10 Scleroderma Clinical Trials in Chicago, IL (2026)

Q: How do I join a clinical trial in Chicago?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Chicago research site will contact you.

Recruiting Scleroderma Studies in Chicago

NCT06195072Recruiting

Platform Clinical Study for Conquering Scleroderma

The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung ...

Chicago, ILPHASE2400 participantsScleroderma Research Foundation, Inc.

View Study Details

NCT05878717Recruiting

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lun...

Chicago, ILPHASE2300 participantsGlaxoSmithKline

View Study Details

NCT06733935Recruiting

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells ...

Chicago, ILPHASE1240 participantsNkarta, Inc.

View Study Details

NCT06470048Recruiting

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

The purpose of this study is to evaluate efficacy, safety and tolerability of s.c. ianalumab administered in participants with diffuse cutaneous systemic sclerosis relative to placebo...

Chicago, ILPHASE2200 participantsNovartis Pharmaceuticals

View Study Details

NCT06655896Recruiting

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse c...

Chicago, ILPHASE296 participantsNovartis Pharmaceuticals

View Study Details

NCT07335562Recruiting

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

The purpose of this study is to compare the efficacy and safety of BMS-986353 versus standard of care in participants with active Systemic Sclerosis...

Chicago, ILPHASE392 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT06655155Recruiting

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

The main purpose of this study is to evaluate the effect and safety of efgartigimod PH20 SC compared to placebo in adults with systemic sclerosis. The study consists of a screening period, a treatment...

Chicago, ILPHASE281 participantsargenx

View Study Details

NCT07295847Recruiting

A Study of AZD0120 in Autoimmune Diseases

This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with system...

Chicago, ILPHASE127 participantsAstraZeneca

View Study Details

NCT05892614Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

This is a 2-Part study with Part A, a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD. The primary ob...

Chicago, ILPHASE225 participantsaTyr Pharma, Inc.

View Study Details

NCT06328777Recruiting

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis...

Chicago, ILPHASE112 participantsCabaletta Bio

View Study Details

About Scleroderma Clinical Trials in Chicago

Scleroderma is an autoimmune connective tissue disease characterized by hardening and tightening of the skin and connective tissues. Systemic sclerosis can also affect internal organs including lungs, kidneys, and heart. Treatment is directed at specific symptoms and organ involvement.

There are currently 10 scleroderma clinical trials recruiting participants in Chicago, IL. These studies are seeking a combined 1,473 participants. Research is being sponsored by Scleroderma Research Foundation, Inc., GlaxoSmithKline, Nkarta, Inc. and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Scleroderma Clinical Trials in Chicago — FAQ

Are there scleroderma clinical trials in Chicago?

Yes, there are 10 scleroderma clinical trials currently recruiting in Chicago, IL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Chicago?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Chicago research site will contact you about next steps.

Are clinical trials in Chicago free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Chicago studies also compensate for your time and travel.

What scleroderma treatments are being tested?

The 10 active trials in Chicago are testing new therapies including novel drugs, biologics, and treatment approaches for scleroderma.

Data updated July 17, 2026 from ClinicalTrials.gov